SOX2 and glioblastoma: Expression of SFRP2 in cell line U-2987MG resulted in transition to a mesenchymal phenotype with a more specific cytoskeletal organization increasing collective migration and invasion, as SFRP2 has been shown to act as a SOX2 antagonist in glioblastoma cells29.